OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - south dakotaPolicy N/A

Homocysteine Testing Coverage Criteria

Customize your policy alerts

Sign up for all blue cross blue shield - south dakota policy alerts

Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage and medical necessity criteria for measurement of plasma homocysteine levels, affecting clinicians ordering homocysteine testing and Blue Cross Blue Shield - South Dakota members.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyHomocysteine Testing Coverage Criteria

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateDec 1, 2009

Last ReviewFeb 1, 2025

Next Review DateN/A

Key ActionDocument clinical indication when ordering homocysteine testing (e.g., borderline B12 200–300 pg/mL or suspected homocystinuria) to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Medically necessary indications listed

2Investigational / not covered uses

83090CPT code listed

200–300Vitamin B12 borderline range

0No direct outcome-improving studies

Coverage and Medical Necessity Criteria

inv-01: Medically Necessary Indications

Covered when ALL of the following are met:

Medically necessary indications: Measurement of plasma homocysteine levels may be considered medically necessary for (1) assessment of individuals with borderline vitamin B12 deficiency (200 to 300 pg/mL) where results will impact management; OR (2) assessment of individuals with suspected or confirmed homocystinuria (cystathionine beta synthase deficiency).

Either indication meets medical necessity per policy.

inv-02: Investigational / Not Medically Necessary Indications

Not covered / Investigational:

Investigational indications: Measurement of plasma homocysteine is considered investigational when the medically necessary criteria above are not met, including but not limited to: screening, evaluation, or management of cardiovascular disease (CVD); and screening, evaluation, or management of venous thromboembolism (VTE) or risk of VTE.

Evidence is insufficient to show improvement in net health outcomes for these uses.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyHomocysteine Testing Coverage Criteria

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateDec 1, 2009

Last ReviewFeb 1, 2025

Next Review DateN/A

Key ActionDocument clinical indication when ordering homocysteine testing (e.g., borderline B12 200–300 pg/mL or suspected homocystinuria) to support medical necessity.

SourceLink

On This Page

inv-04: Evidence-based coverage considerations

Evidence summary-based coverage considerations:

Clinical utility requirement: A test is clinically useful only if results inform management decisions that improve net health outcome (eg, lead to correct or more effective therapy or avoid unnecessary therapy/testing).

Definition of clinical utility from policy.

Venous thromboembolic disorders: Randomized trials and systematic reviews show homocysteine-lowering interventions did not significantly reduce VTE rates; there is insufficient evidence that testing to guide supplementation reduces VTE risk.

Section summary: VTE evidence.

Homocystinuria evidence: No published, adequately powered studies were identified that directly evaluated whether using homocysteine testing to determine homocystinuria status improves health outcomes.

Section summary: Homocystinuria.

Vitamin B12 deficiency evidence: No published, adequately powered studies were identified that directly evaluated whether using homocysteine testing to determine vitamin B12 status improves health outcomes; metabolite testing (MMA, homocysteine) may be used to clarify borderline or discordant vitamin results but outcome benefit of testing is not demonstrated.

Section summary: Vitamin B12 deficiency.

Specific Covered Indications

inv-60: Borderline vitamin B12 (200–300 pg/mL) where results affect management; suspected or confirmed homocystinuria.

Covered indications — measurement generally considered when ALL of the following apply:

Borderline B12 or homocystinuria: Measurement of plasma homocysteine is indicated for individuals with borderline serum vitamin B12 (200–300 pg/mL) when results will affect management, and for suspected or confirmed homocystinuria.200–300 pg/mL

From policy: borderline B12 range and homocystinuria indication.

inv-61: Evaluation of idiopathic, recurrent, early-onset, or unusual-site venous thromboembolism; investigation of suspected vitamin B12 or folate deficiency when serum vitamin levels are borderline or equivocal.

When to consider testing:

VTE and equivocal vitamin testing: Evaluation of idiopathic, recurrent, early-onset, or unusual-site venous thromboembolism; and investigation of suspected vitamin B12 or folate deficiency when serum vitamin levels are borderline or equivocal.

Policy lists VTE contexts and the role in clarifying equivocal vitamin tests.

inv-62: Evaluation of individuals asymptomatic but at risk for VTE and individuals who have had VTE events to inform decisions about homocysteine-lowering therapy.

Purpose for testing in VTE contexts:

Inform management: Evaluation of individuals asymptomatic but at risk for VTE and individuals who have had VTE events when testing is intended to inform decisions about homocysteine-lowering therapy (eg, consideration of B‑vitamin supplementation).

Policy states purpose is to inform whether to lower homocysteine.

inv-63: Suspected or known homocystinuria — Testing intended to inform management decisions such as whether to lower homocysteine levels.

Indication and purpose:

Suspected/known homocystinuria: Testing for suspected or known homocystinuria to inform management decisions such as whether to lower homocysteine levels; measure homocysteine in suspected cases and first-degree relatives per guidance.

Refer severe cases to metabolic specialist and nutritionist as noted in policy.

inv-64: Asymptomatic individuals at risk for vitamin B12 deficiency and those with known vitamin B12 deficiency — Testing intended to inform management decisions.

When metabolite testing may be useful:

B12 deficiency contexts: Asymptomatic individuals at risk for vitamin B12 deficiency and those with known vitamin B12 deficiency may have homocysteine (and/or MMA) measured when results would inform management decisions; metabolites are used when initial vitamin tests are borderline or clinical findings are discordant.

Policy and UpToDate recommend metabolite testing to clarify borderline/inconclusive vitamin results.

inv-65: Evaluation of suspected homocystinuria; confirmation of vitamin B12 deficiency when initial vitamin B12 or folate tests are borderline/inconclusive or when clinical findings are discordant.

Specific diagnostic contexts:

Confirmatory and referral guidance: Evaluation of suspected homocystinuria; confirmation of vitamin B12 deficiency when initial vitamin B12 or folate tests are borderline/inconclusive or when clinical findings are discordant. In rare severe hyperhomocysteinemia associated with homocystinuria, refer to metabolic disease specialist and nutritionist.

Guidance from UpToDate and policy summaries.

inv-66: Referenced literature and guidelines discuss homocysteine measurement in multiple clinical contexts; references guide clinical use.

Context from referenced literature and guidelines:

Literature contexts: Referenced literature and guidelines discuss homocysteine measurement in contexts including cardiovascular risk assessment, stroke prevention, venous thromboembolism, bone health/fracture risk, cognitive disorders, and suspected inherited homocystinuria; however, guideline bodies generally do not recommend routine homocysteine screening for primary prevention.

References and guideline statements cited in policy.

Not Covered / Investigational Uses

Measurement of plasma homocysteine for the purposes of screening, evaluation, or routine management of cardiovascular disease (CVD) and venous thromboembolism (VTE) is considered investigational and is not covered. The evidence is insufficient to demonstrate that homocysteine testing in these contexts leads to improved net health outcomes.

Use of homocysteine testing solely to attempt to reduce cardiovascular events or mortality—without a clear, evidence-based plan showing how results will change management—is not covered. Pooled randomized trials and meta-analyses of vitamin B supplementation found no significant benefit for coronary heart disease events or overall mortality, and the clinical significance of any modest stroke risk reduction is uncertain.

Randomized trials evaluating homocysteine-lowering vitamin supplementation did not demonstrate a statistically significant reduction in recurrent or symptomatic VTE. Therefore, homocysteine testing to direct vitamin supplementation with the goal of reducing recurrent VTE is not covered.

There are no adequately powered published studies showing that using homocysteine testing to guide homocysteine‑lowering therapy reduces VTE risk or that testing to diagnose homocystinuria or vitamin B12 deficiency improves health outcomes. Consequently, ordering homocysteine testing for these therapeutic or outcome‑improvement claims is not covered.

Major guideline groups do not endorse routine homocysteine testing for cardiovascular risk assessment or primary prevention. Homocysteine testing to guide routine B‑complex vitamin supplementation for prevention of cardiovascular events is therefore not covered.

No additional explicit tests or clinical indications are listed as not covered in the excerpted coding and policy summary beyond the investigational uses described above.

Coding and Test Codes

Codes table referencedmixed

No codes listed

Covered CPT CodesCPTCovered

83090

Homocysteine

HCPCSHCPCS

No code(s)

No HCPCS codes listed in this section

Type of Servicemixed

Pathology/Laboratory

Type of Service

Place of Servicemixed

Outpatient

Place of Service

inv-24: Target homocysteine for newborns with homocystinuria — maintain plasma homocysteine below 11 micromol/L

Target for newborns with homocystinuriaMaintain plasma homocysteine below 11 micromol/L (treated immediately after newborn screening)

ContextApplied to newborns identified by newborn screening after confirmation of hyper-methioninemia

PurposeEarly treatment to reduce morbidity and mortality associated with homocystinuria

inv-25: Typical laboratory reference ranges — MMA 70 to 270 nmol/L; homocysteine 5 to 15 micromol/L (lab-dependent)

Methylmalonic acid (MMA) typical range70 to 270 nmol/L (laboratory-dependent example)

Total plasma homocysteine typical range5 to 15 micromol/L (laboratory-dependent)

Note on assay dependenceLaboratory-specific and assay-specific cutoffs should be used; examples provided are illustrative

Provider Actions, Documentation, and Billing

Prior Authorization

Prior approval not applicable

No prior authorization is required for homocysteine testing under this policy; prior approval is listed as not applicable.

Prior Authorization

No explicit prior authorization statements

The policy contains no explicit prior authorization statements for homocysteine testing in this section.

Prior Authorization

No specified prior authorization requirements

This segment does not specify any prior authorization requirements for homocysteine testing.

Prior Authorization

Prior authorization may be requested to justify management intent

Prior authorization may be requested to document that homocysteine testing is intended to inform management in patients with suspected or known homocystinuria or when clarifying borderline vitamin B12 results.

Use when testing is ordered to inform management decisions for suspected/known homocystinuria or equivocal B12/folate results.

Prior Authorization

Medical-necessity prior authorization for routine CVD/VTE screening

Prior authorization may be required when homocysteine testing is ordered for routine cardiovascular risk assessment or screening rather than to clarify borderline B12 or to evaluate suspected homocystinuria.

Billing Rule

Coding requirement — use CPT 83090

Report homocysteine testing using CPT code 83090 as listed in the policy's coding section.

Ensure claims use CPT 83090 for total homocysteine reporting.

Step Therapy

Therapeutic context — initial vitamin therapy dosing

When treating elevated homocysteine levels, initial therapy may include folic acid 1 mg/day with vitamin B6 and B12; folic acid can be increased up to 5 mg/day depending on levels and clinical context.

Normalization may begin within two weeks and additional lowering can occur by six weeks.
Initial folic acid 5 mg/day is advised for homocysteine >30 µmol/L or chronic renal failure.

Step Therapy

No step therapy requirements specified

No step therapy requirements are specified in this portion of the policy.

Note

Public health context — folic acid fortification

The policy notes public health folic acid fortification as background that may affect the incremental effectiveness of homocysteine-lowering interventions; it does not establish step therapy requirements.

Note

Comparator practice — routine care without testing

The comparator practice considered in evidence reviews is routine care without homocysteine testing (and no supplementation).

Step Therapy

Confirmatory metabolite testing before initiating therapy

Consider confirming vitamin B12 deficiency with at least one metabolite (MMA or homocysteine) when initial vitamin B12 or folate results are borderline or discordant with clinical findings before initiating therapy.

Ideally seek at least two biochemical abnormalities in asymptomatic individuals; use laboratory-specific reference ranges (e.g., MMA 70–270 nmol/L; homocysteine 5–15 µmol/L as examples).
Repeat testing at 2–4 weeks may be appropriate for incidental mild abnormalities before treatment.

Note

Documentation Required

Indication documentation required on orders

Documentation for homocysteine testing orders should state that testing is for either assessment of borderline vitamin B12 deficiency (200–300 pg/mL) where results will impact management, or for suspected/confirmed homocystinuria.

Documentation Required

Required clinical indication and supporting lab results

Required documentation should include the clinical indication (e.g., evaluation of suspected hyperhomocysteinemia related to idiopathic, recurrent, young, or unusual-site VTE) and available vitamin B12/folate test results when ordering homocysteine or MMA.

Include relevant clinical findings (e.g., macrocytic anemia or neurologic signs) when ordering metabolites to evaluate B12 status.

Documentation Required

Evidence requirement — show clinical utility

Studies used to support clinical utility must demonstrate that test results change treatment decisions and overall patient management and lead to improved net health outcomes.

Documentation Required

Order justification — document how results will inform management

Orders should document the clinical purpose tied to specific populations (suspected/known homocystinuria or risk/known vitamin B12 deficiency) and how results would inform management decisions.

Documentation Required

Required clinical documentation for metabolite testing

When ordering homocysteine or MMA to evaluate vitamin B12 status, document initial B12 and folate test results (including if borderline or inconclusive), relevant clinical findings, and rationale for metabolite testing; use laboratory-specific reference ranges.

Examples of typical ranges: MMA 70–270 nmol/L; homocysteine 5–15 µmol/L (laboratory-dependent).

Billing Rule

Billing and documentation — use correct codes and retain records

Use appropriate CPT/HCPCS and diagnosis coding for outpatient pathology/laboratory services and retain documentation consistent with policy and recordkeeping.

CPT code for homocysteine: 83090.

Denial Risk

Investigational uses — risk of denial for CVD/VTE screening

Testing for homocysteine when used for screening, evaluation, or routine management of cardiovascular disease or venous thromboembolism is considered investigational and may be denied.

Do not order homocysteine testing for routine CVD or VTE evaluation without clear management intent supported by documentation.

Denial Risk

Potential denial triggers — weak or unsupported indications

Claims for homocysteine testing ordered solely for weak or unsupported indications (e.g., routine asymptomatic screening without clinical justification) may be at risk for denial.

Note

No procedural/billing denial triggers specified

The policy emphasizes evidence and clinical utility rather than procedural or billing triggers; no explicit procedural billing denial triggers are specified in this segment.

Denial Risk

Evidence-based denial risk — no outcome benefit demonstrated

Lack of peer-reviewed evidence that homocysteine testing improves health outcomes could lead to coverage denial when testing is submitted to justify improved outcomes.

Randomized trials and reviews did not identify adequately powered studies showing that testing to guide treatment improves morbidity or mortality.

Denial Risk

Evidence-based denial risk — do not claim outcome improvement

Claims for homocysteine testing may be denied when submitted with assertions that testing improves health outcomes, since no identified peer-reviewed evidence shows such benefit for determining vitamin B12 status.

Billing Rule

Claims reporting — use CPT 83090

Submit claims using the appropriate CPT code 83090 for homocysteine; incorrect coding may cause claim processing issues.

Ordering and Documentation Requirements

Documentation Required

Document purpose: borderline B12 or suspected homocystinuria

Ordering clinician should document that testing is for either borderline vitamin B12 evaluation (200–300 pg/mL) or suspected/confirmed homocystinuria; specify the population and intent of testing.

Documentation Required

Document clinical indication and correlate with B12/folate tests

Orders should document the clinical indication (VTE risk assessment, suspected B12/folate deficiency) and correlate results with vitamin B12 and folate testing when applicable.

Note

No ordering-provider restrictions specified

No specific ordering-provider restrictions are provided in this policy; however, the order should frame testing as a tool to inform management decisions in at‑risk or affected patients.

Documentation Required

Specify clinical population and management intent on orders

Orders should specify the clinical population and management intent (e.g., suspected homocystinuria or vitamin B12 deficiency) to justify testing.

Documentation Required

Order when clinically indicated; refer severe cases

Order homocysteine testing when clinically indicated by a specialist or primary provider documenting suspicion for homocystinuria or need to clarify borderline/discordant B12 results; consider referral for severe hyperhomocysteinemia.

Refer patients with severe hyperhomocysteinemia associated with homocystinuria to a metabolic specialist and nutritionist.

Note

No additional ordering-provider restrictions noted

No specific ordering-provider restrictions are stated elsewhere in this section of the policy.

Frequency and Follow-up Guidance

inv-67: No explicit frequency limits stated in this portion of the document.

Frequency limits (documented)No explicit frequency limits stated in this portion of the document.

ImplicationOrdering frequency should be guided by clinical context and treating clinician judgment

Related guidanceLaboratory-specific practices and follow-up recommendations (see UptoDate) may inform timing

inv-69: No frequency limits specified in this segment.

Frequency limits (specified)No frequency limits specified in this segment.

Outcome time frameRelevant clinical outcomes (e.g., DVT or PE) are typically assessed over 3 or more years, per outcomes section

Clinical discretionRepeat testing intervals should reflect clinical scenario and evidence-based follow-up guidance

inv-71: Homocysteine/MMA follow-up — Repeat testing at 2-4 weeks may be appropriate for incidental mild abnormalities before treatment (per UptoDate guidance).

Repeat testing interval for incidental mild abnormalitiesRepeat testing at 2–4 weeks may be appropriate before initiating treatment (per UpToDate guidance)

When to repeat earlierRepeat earlier if clinical condition worsens or expected response to therapy is not observed

Tests referencedApplies to homocysteine and/or MMA as follow-up metabolites when initial findings are mild/incidental

inv-72: Homocysteine (CPT 83090) — Coding reference for frequency section.

CPT coding for homocysteineHomocysteine reported under CPT code 83090

Use in frequency sectionReference CPT 83090 when documenting test frequency or claims

Claims guidanceEnsure appropriate CPT/HCPCS coding (83090) to avoid claim processing issues

Definitions and Reference Ranges

inv-51: Hyperhomocysteinemia classification — Severity categories and normal range examples.

Normal range (example)Total plasma homocysteine: 5–15 micromol/L

Severity categoriesModerate: 15–30 micromol/L; Intermediate: 31–100 micromol/L; Severe: >100 micromol/L

Desirable levelLevels below 10 micromol/L are considered desirable

inv-52: Homocystinuria — Autosomal recessive disorder with markedly elevated homocysteine and clinical features; B6-responsiveness noted.

DefinitionHomocystinuria (cystathionine beta-synthase [CBS] deficiency) is an autosomal recessive disorder characterized by markedly elevated plasma homocysteine and methionine

Phenotypic variantsIncludes B6-responsive and B6-nonresponsive variants with variable severity

Clinical featuresMay include developmental delay, Marfanoid habitus, ocular lens dislocation, thromboembolism, and premature atherosclerosis

inv-53: Hyper-homocysteinemia — Elevation associated with increased VTE risk and vitamin B12/folate deficiency causes.

Association with VTEElevated homocysteine (hyper-homocysteinemia) has been associated with increased risk for venous thromboembolic disease, though it is a relatively weak prothrombotic factor

CausesCan result from vitamin B12, folate, or B6 deficiency, genetic enzyme defects, chronic disease, medications, or lifestyle factors

Clinical implicationDetecting elevation may prompt evaluation for B12/folate deficiency or inherited disorders rather than routine population screening

inv-54: Clinically Useful — Definition of clinical utility used in policy.

Policy definition of clinical utilityA test is clinically useful if results inform management decisions that improve net health outcome (e.g., lead to correct or more effective therapy or avoid unnecessary therapy)

ApplicationClinical utility requirement guides coverage decisions for homocysteine testing

Evidence implicationDemonstration that test results change management and improve outcomes is required to support coverage beyond limited indications

inv-55: Measurement definition — Measurement of plasma homocysteine level to inform management decisions such as initiating homocysteine-lowering therapy.

Measurement purposeMeasurement of plasma homocysteine level to inform management decisions such as initiating homocysteine-lowering therapy (e.g., vitamin B/folic acid supplementation) or dietary modifications

ContextsUsed to evaluate suspected homocystinuria and to clarify borderline vitamin B12/folate results

Confirmatory roleOften measured alongside MMA to confirm B12 deficiency when vitamin levels are equivocal

inv-56: Homocystinuria — Rare autosomal recessive disorder characterized by markedly elevated serum and urine homocysteine; clinical phenotype noted.

Disorder summaryHomocystinuria is a rare autosomal recessive disorder with markedly elevated serum and urine homocysteine and characteristic clinical phenotype

Newborn managementNewborns identified by screening are treated early to normalize homocysteine and reduce complications

Specialist referralRefer patients with severe hyperhomocysteinemia to metabolic specialists and nutritionists

inv-57: MMA and homocysteine testing — Metabolite tests used as adjuncts to confirm B12 deficiency when vitamin levels are borderline or clinical presentation is discordant.

Adjunct testing roleMMA and homocysteine are used as adjunct metabolites to confirm vitamin B12 deficiency when vitamin levels are borderline or clinical findings are discordant

Sensitivity evidenceA 1994 series reported 99.8% sensitivity for elevated MMA or homocysteine in confirmed B12 deficiency cases

RecommendationUse at least one metabolite (MMA or homocysteine) to confirm B12 deficiency when initial tests are equivocal

inv-58: Homocysteine — Total homocysteine analyte measured and reported under CPT code 83090.

Analyte and CPTTotal homocysteine (reported as homocysteine) — CPT code 83090

Coding notePolicy instructs use of CPT 83090 for claims reporting; ensure correct code to avoid processing issues

Test namingReferred to as homocysteine or total plasma homocysteine in clinical and coding sections

inv-59: Homocystinuria — Inherited disorder discussed in referenced guidelines (e.g., GeneReviews).

Guideline and reference mentionHomocystinuria and its management are discussed in resources such as GeneReviews and guideline publications cited in the policy

Evidence basePolicy references GeneReviews, guideline reviews, and UpToDate for clinical context on homocystinuria

Testing indicationTesting is generally reserved for suspected cases and first-degree relatives per referenced guidance

Background and Evidence Summary

Homocysteine is a sulfur‑containing amino acid typically reported as total plasma homocysteine (including oxidized forms). Elevated plasma concentrations can result from inherited enzyme defects (for example, cystathionine β‑synthase deficiency), deficiencies of vitamin B12, folate, or vitamin B6, certain medications, comorbid illnesses, and lifestyle factors.

Evidence from pooled randomized trials does not support the use of homocysteine testing with the expectation of reducing major cardiovascular events or mortality. Large systematic reviews and meta‑analyses of homocysteine‑lowering interventions (B‑vitamin supplementation) generally showed no significant effect on CHD events or all‑cause mortality; any observed reduction in stroke risk was considered of uncertain clinical significance.

Trials of homocysteine‑lowering interventions (folic acid and B‑vitamins) have not demonstrated a significant reduction in coronary heart disease events, VTE, or all‑cause mortality. Systematic reviews and individual randomized trials therefore do not support homocysteine‑lowering therapy as improving these clinical outcomes.

No published, peer‑reviewed studies adequately powered to determine whether use of homocysteine testing to diagnose homocystinuria leads to improved health outcomes were identified. The available evidence does not establish that testing for homocystinuria, by itself, changes morbidity or mortality.

There are no adequately powered studies showing that using homocysteine testing to determine vitamin B12 deficiency improves health outcomes. Thus, relying on homocysteine measurement to define B12 status with the expectation of improved clinical outcomes is not supported by identified evidence.

Policy History and Revision Notes

2025-02Annual review / RenewalLatest

Policy renewed following annual review in February 2025.

2024-02Annual review / Revision

Policy revised during the February 2024 annual review.

2023-07Annual review / Revision

Policy revised during the July 2023 annual review.

2022-07Annual review / Revision

Policy revised during the July 2022 annual review.

2021-07Annual review / Revision

Policy revised during the July 2021 annual review.

2020-07Annual review / Renewal

Policy renewed following the July 2020 annual review.

2019-07Annual review / Revision

Policy revised during the July 2019 annual review.

2018-07Annual review / Revision

Policy revised during the July 2018 annual review.

2017-07Annual review / Renewal

Policy renewed following the July 2017 annual review.

2016-07Annual review / Revision

Policy revised during the July 2016 annual review.

2015-08Annual review / Revision

Policy revised during the August 2015 annual review.

2014-09Annual review / Revision

Policy revised during the September 2014 annual review.

2013-10Annual review / Renewal

Policy renewed following the October 2013 annual review.

2012-12Annual review / Revision

Policy revised during the December 2012 annual review.

2012-07Annual review / Renewal

Policy renewed following the July 2012 annual review.

2011-08Annual review / Renewal

Policy renewed following the August 2011 annual review.